
Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).
What Happened: According to Reuters, Pfizer Inc (NYSE:PFE) won the bidding war against Novo Nordisk and will purchase Metsera for $10 billion. The board of Metsera accepted Pfizer’s offer, stating that Novo’s bid carried too much legal and regulatory risks following antitrust concerns raised by the Federal Trade Commission.